In our study, we confirmed that CREB3L1 is significantly correlated with the sensitivity of several anti-cancer drugs, especially targeted therapy agents, such as cabozantinib, lenvatinib, and dabrafenib. The gene discussed is CREB3L1; the disease is cancer.